The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial

Slični predmeti

• Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
  od: Wajja, A, i dr.
  Izdano: (2018)
• Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
  od: Wajja, A, i dr.
  Izdano: (2024)
• Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
  od: Wajja, A, i dr.
  Izdano: (2023)
• A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
  od: Rowland, R, i dr.
  Izdano: (2012)
• Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trial
  od: Abaasa, A, i dr.
  Izdano: (2023)